AMICOS: Peripheral Artery Disease (PAD) : Its Effects on Bone

Sponsor
Centre Hospitalier Régional d'Orléans (Other)
Overall Status
Recruiting
CT.gov ID
NCT05034848
Collaborator
(none)
200
1
1
17.1
11.7

Study Details

Study Description

Brief Summary

Prevalence of PAD and osteoporosis (OP) both get higher with age. Clinical and epidemiologic evidence have showed an increased cardiovascular risk in OP and bone loss and fragility fractures in patient with cardiovascular disease.

This study will examine the relationship between vascular disease in legs and sBMD and vBMD at trabecular and cortical sites and bone microarchitecture.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Assessment of BMD by DXA and HRpQCT
N/A

Detailed Description

The primary goal of our study is to determinate if presence of PAD is associated with lower sBMD and vBMD values at the tibias, assuming that BMD should be more alterate in the predominant vascular impairement site.

Our secondary objectives are to :
  • determine if severity of PAD quantified by ankle brachial index ABI is associated to a decrease of BMD values defined by T-Score at the left hip, spine and legs, but also with volumetric values, assessed by HRpQCT at the non dominant radius and at both tibias.

  • determine the prevalence of osteoporosis in our population

  • To evaluate the relationships between ;

  • lipids and bone parameters

  • vit D and parathormone with PAD severity

  • levels of physical activity and both vascular and bone impairments

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
observational, interventional, non comparative, prospective, monocentric open studyobservational, interventional, non comparative, prospective, monocentric open study
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Peripheral Artery Disease (PAD) : Its Effects on Bone
Actual Study Start Date :
Mar 31, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: PAD group

PAD patients, diagnosis after undergoing an echo-doppler in the Vascular Medicine Department of Orleans regional Hospital

Procedure: Assessment of BMD by DXA and HRpQCT
DXA : BMD assessment at the left hip, rachis and both legs HRpQCT : Volumic Bone mineral density, cortical and trabecular parameters, at the non dominant radius and legs Biological samples

Outcome Measures

Primary Outcome Measures

  1. Bone Mineral Density (BMD) volumic values at the tibias of PAD (Peripheral Artery Disease) patients [Day 0]

    BMD volumic values are BMD volumetric bone mineral density (mg HA/cm3)

Secondary Outcome Measures

  1. Bone Mineral Density (BMD) measurement by DXA [Day 0]

    Relations between areal BMD results (DXA) at the hip and lumbar spine and the ankle brachial index measured at the two legs.

  2. Correlation between microstructural parameters and ankle brachial index results [Day 0]

    The following micro structural parameters assessed by HRpQCT at both tibias will be : Dtrab : volumetric trabecular bone mineral density (mg HA/ cm3), Dinn : inner trabecular bone density (mg HA/cm3), Dmeta: metatrabecular bone density (mg HA/cm3), Dcort: volumetric cortical bone mineral density (mg HA/cm3), D100: total volumetric bone mineral density (mg HA/cm3), Tb.Th: trabecular thickness (mm), Tb.N: trabecular number (mm-1); Tb.Sp: trabecular separation (mm), Ct.Th: cortical thickness (mm); Tb1.NSD: intra-distribution individual separation (mm), BV / TV: trabecular bone volume (%).

  3. Comparison between microstructural parameters at tibias [Day 0]

    comparison between bone microarchitecture parameters at the tibia: the parameters will be compared between the most severely limb and the contralateral one.

  4. Correlation between Lipid and bone parameters [Day 0]

    We will study the relation between lipidic and bone parameters. Potential correlations between on the one hand (lipid parameters: total and HDL-cholesterol, triglyceridemia, LDL-cholesterol calculation) and on the other hand bone parameters: vBMD volumetric bone mineral density (mg HA/cm3) Ct.BMD: cortical volumetric bone mineral density (mg/cm3); Tb.BMD: trabecular volumetric bone mineral density (mg HA/cm3)

  5. Percentage of densitometric osteoporotic patients [Day 0]

    percentage of densitometric osteoporotic patients in the population

  6. Evaluation of risk of fracture [Day 0]

    The risk of fracture at 10 years will be evaluate by the Fracture Risk Assessment Tool (FRAX) survey. The FRAX® tool was developed by the then WHO Collaborating Centre for Metabolic Bone Diseases (1991-2010) at the University of Sheffield. It was launched in 2008 following approximately 10 years of meta-analyses of a variety of risk factors for osteoporotic fracture. Although not the only fracture prediction tool available, FRAX® is the only risk calculator which has been calibrated to rates of fracture and mortality per individual country and has been shown to identify a risk amenable to available treatments.

  7. Evaluation of cardiovascular risk [Day 0]

    Cardiovascular risk assessment using the SCORE tool (Systematic Coronary Risk Estimation). Four levels of risk are defined: Very high cardiovascular risk ≥ 10%; High risk, which includes subjects with major or particularly high risk factors (familial hypercholesterolemia, severe hypertension, etc.) and those with a score between 5 and 10%; Moderate risk, which concerns patients with a score between 1 and 5%; Low risk, which includes subjects with a score < 1%;

  8. Correlation between microstructural parameters at tibias and radius [Day 0]

    comparison between bone microarchitecture at the tibia and of the radius. The following micro structural parameters assessed by HRpQCT at tibias and radius will be : Dtrab : volumetric trabecular bone mineral density (mg HA/ cm3), Dinn : inner trabecular bone density (mg HA/cm3), Dmeta: metatrabecular bone density (mg HA/cm3), Dcort: volumetric cortical bone mineral density (mg HA/cm3), D100: total volumetric bone mineral density (mg HA/cm3), Tb.Th: trabecular thickness (mm), Tb.N: trabecular number (mm-1); Tb.Sp: trabecular separation (mm), Ct.Th: cortical thickness (mm); Tb1.NSD: intra-distribution individual separation (mm), BV / TV: trabecular bone volume (%).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • PAD patients defined by an Ankle brachial index < 0.9

  • Written consent

  • Patient affiliated with a social security organism

Exclusion Criteria:
  • Age < 18 years

  • Pregnancy or risk of pregnancy

  • Patients Under guardianship

  • Patient with known PAD who had been previously treated by surgery or endovascular pathway

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHR d'ORLEANS Orleans France 45067

Sponsors and Collaborators

  • Centre Hospitalier Régional d'Orléans

Investigators

  • Principal Investigator: Eric LESPESSAILLES, Dr, CHR Orleans

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Centre Hospitalier Régional d'Orléans
ClinicalTrials.gov Identifier:
NCT05034848
Other Study ID Numbers:
  • CHRO-2018-13
First Posted:
Sep 5, 2021
Last Update Posted:
Sep 5, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Régional d'Orléans
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 5, 2021